SingleTimeMicroneedles
SingleTimeMicroneedles
SingleTimeMicroneedles are improving drug delivery with multi-dose patches that improve immunity and reduce supply chain costs.
SingleTimeMicroneedles
SingleTimeMicroneedles’ (STM) mission is to improve domestic and global health and wellness through equitable access to highly effective vaccines.
STM has developed the only microneedle platform that can deliver single or multi- longitudinal dose vaccines/therapeutics in one patch.
To support greater vaccine deployment, STM’s technology eliminates the need for booster administrations, cold-chain transportation/storage, even for mRNA biologics, reduces the burden on medical personnel, and creates no biohazard waste.
For patients, STM’s patch increases access by reducing repeat clinic visits, improves their immunity, and eliminates pain.
Humans
Improving health from biologics to therapeutics to nutraceuticals
Animals
Improving animal welfare from home to farm
Social Impact
Improving access to wellness from the individual to whole communities
SingleTimeMicroneedles Core Technology
An easily-administered patch applied to the skin to embed arrays of microneedles (MNs). Minutes later, the patch is removed and MNs are imperceptibly embedded in superficial skin.
The MNs are a biodegradable polymer, like those in sutures, and are engineered to release vaccines immediately, repeatedly, or over a period of time, in a single application.
This technology supports all types of vaccines and therapeutics, including subunit protein-based antigens, vector-based vaccines, mRNAs, or any compound that benefits from multiple/longitudinal dosing.
Patches are stabilized against high temperatures to avoid the need for a refrigerated supply chain and affirming the antigenicity while in the skin.
STM patches are also being planned for medications, animal applications, and certain compounds in the nutraceutical market.
Growth
SingleTimeMicroneedles Research
Tran, K. T. M., Gavitt, T. D., Le, T. T., Graichen, A., Lin, F., Liu, Y., … Nguyen, T. D. (2022). A Single‐Administration Microneedle Skin Patch for Multi‐Burst Release of Vaccine against SARS‐CoV‐2. Advanced Materials Technologies. https://doi.org/10.1002/admt.202200905
Tran, K. T. M., Gavitt, T. D., Farrell, N. J., Curry, E. J., Mara, A. B., Patel, A., Brown, L., Kilpatrick, S., Piotrowska, R., Mishra, N., Szczepanek, S. M., & Nguyen, T. D. (2021). Transdermal microneedles for the programmable burst release of multiple vaccine payloads. Nature biomedical engineering, 5(9), 998–1007. https://doi.org/10.1038/s41551-020-00650-4
Press
2024 SXSW Pitch Competition Winners
SingleTimeMicroneedles, CEO Jasdeep Singh, Wins 2024 SXSW Pitch Competition
SingleTimeMicroneedles, CEO Jasdeep Singh, Wins 2024 SXSW Pitch Competition
STM selected as a finalist for SXSW 2024
SXSW Pitch Finalists and Alternates Announced
World Vaccine Congress Washington DC Start-Up Selection
Researchers Develop Strategy to Thermally Stabilize Microneedle Vaccine Technology
Bench To BARDA Panel Series
GBETA Medtech Announces New Cohort
Press History
SingleTimeMicroneedles Founders
Thanh Duc Nguyen, Ph.D.
Chief Technology Officer
Dr. Nguyen is an associate professor of mechanical engineering at the University of Connecticut who is an innovator, nine-time patent holder, and research leader who has raised over $5M in grant and private funding. Thanh founded two start-up companies and has an extensive pharmaceutical and private industry network.
Jasdeep Singh, Ed.D., MBA
Chief Executive Officer
Dr. Singh has managed a variety of organizations, led a $500K seed round at a $3M valuation, and led schools with over 150 employees and multimillion dollar budgets. Jasdeep has also been a team leader in numerous negotiations, closed an international licensing agreement, and brings consulting experience and a VC and angel investor network.
Team
Nicholas Farrell
Nicholas is a driven and adaptive engineer and researcher. He is a former member of Dr.
Nguyen’s research group, and is a co-author of the Nguyen lab’s 2021 publication (see
publications section). In addition to an academic career in biomedical research, Nicholas also
brings a wealth of experience in quality control, computer science, and manufacturing
automation from his career in test engineering.
Dr. Steven Szczepanek
Dr. Steven Szczepanek is an expert in infectious diseases and vaccinology. His background in microbiology, immunology, and pathology all contribute to his work in the molecular development of vaccines for both humans and animals. He has worked with bacterial pathogens, viruses, and pathogenic fungi and has an interest in immune dysregulation in the context of both chronic diseases and vaccine enhanced disease.
Most of Dr. Szczepanek’s research is associated with respiratory diseases, although he maintains interest in pathogens of all body systems. Much of his effort in the area of vaccines and immunotherapeutics is on pathogens of high consequence, which requires work in high containment laboratories. Dr. Szczepanek is currently a professor in the department of Pathobiology at the University of Connecticut and he is a PI in the Center of Excellence for Vaccine Research.
Advisors
Richard Hobson
Richard Is the Founder of Herdsy an Agritech firm that Richard has grown into an international award-winning company, winning awards in China, UK, Europe & South Africa. Richard has a diverse skill set and brings with him a wealth of experience and contacts in both the Start-up and the Animal Ag arena from across the globe that will aid SingleTimeMicroneedles in its ambitious global growth strategy.
Investors
Health Advance Partners
Health Advance Partners is a leading investment firm at the forefront of driving innovation and transformation in the healthcare sector. With a mission to revolutionize patient care and improve healthcare outcomes, we specialize in identifying and investing in promising healthcare companies, clinical services, and pharmaceutical ventures. Our seasoned team of investors and industry experts brings a wealth of experience and expertise to every investment opportunity, strategically guiding portfolio companies towards sustainable growth and success. Through strategic partnerships, forward-thinking investments, and a commitment to excellence, Health Advance Partners is shaping the future of healthcare, one investment at a time. Visit our website to learn more: https://healthadvancepartners.com/
Armond Davis
Founder and Managing Partner of The Paragon Group
Armond Davis is the Founder and Managing Partner of The Paragon Group, a venture capital firm. Launched in 2022, the firm invests exclusively in businesses owned and run by female or ethnically diverse founders who are in the pre-seed or seed stage of growth.
The firm is industry agnostic, and believes that there are opportunities to invest in founders who are not in tech that can provide outsized returns. Armond founded the firm to marry his experience in equity portfolio management with that of owning and operating multiple businesses for over 17 years.
Having survived the Great Recession as a business owner, he is uniquely qualified to help guide today’s founders thru the current economic environment. His approach to working with founders is focused on building them into the best version of themselves, because if you can operate as the best version of yourself, then the best version of your business will follow.
Reach SingleTimeMicroneedles
Improve injection-based vaccines and deployment today.
400 Farmington Ave, Rm 1844
Farmington, CT 06032
+1 860-847-0138